The collaboration intends to develop a pilot program using Medtronic’s Reveal LINQ Insertable Cardiac Monitoring system to identify cardiac arrhythmias in patients receiving dialysis.

Medtronic renal care solutions vice-president Ven Manda said: "Medtronic recently announced data at the American Society of Nephrology meeting that showed a higher incidence of arrhythmias in patients receiving hemodialysis.

"We are pleased to pursue this collaboration with DaVita to monitor more patients and gather additional data that will further our understanding of the relationship between dialysis and cardiac events in ESRD patients."

DaVita HealthCare Partners clinical innovation and public policy vice-president Mahesh Krishnan said: "Given the high incidence rate of cardiovascular disease and events in ESRD patients, we believe that by collaborating with Medtronic, we can gain knowledge to help improve the lives of ESRD patients."

Medtronic also announced the new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices for the treatment of heart failure, including a significant reduction in all-cause 30-day readmissions after heart failure hospitalizations.

The company said that its CRT devices have been shown to reduce mortality and improve patient patient quality of life in numerous randomized clinical trials.

Image: The world headquarters of Medtronic, Fridley, Minnesota, USA. Photo: courtesy of Bobak Ha’Eri.